828 / 1835
PD-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin
Lymphoma after Brentuximab Vedotin Failure: Safety, Efficacy, and
Biomarker Assessment
Philippe Armand, et al Blood 2015 126:584
•
Eleven patients had evaluable pre-treatment tumor tissue (archival or obtained for
study). Among them, 10 (91%) were PD-L1+ by
immunohistochemistry (IHC).
•
Among 6 available tumor samples obtained at week 13, 4 (57%) were PD-L1+.
Additionally, 10/10 patients assessed for PD-L2 expression by IHC showed high
levels of PD-L2 staining.
•
Based on
flow cytometry
analyses, a significant increase was observed at the 13-
week time point in the absolute number of circulating total lymphocytes, T cells
(CD4 and CD8 subsets), as well as NK cells.
•
NanoString RNA profiling
of pre- and post-treatment blood samples showed that
several prespecified gene expression signatures were significantly upregulated with
treatment, including the
10-gene IFN-γ-induced signature
, the 18-gene expanded
immune signature, and the 13-gene TCR signature.